Literature DB >> 11937249

Distressful symptoms after radical radiotherapy for urinary bladder cancer.

Lars Henningsohn1, Hans Wijkström, Paul W Dickman, Karin Bergmark, Gunnar Steineck.   

Abstract

BACKGROUND: Radical radiotherapy for muscle-invasive urinary bladder cancer can sterilize the tumour with preserved organ function. Here we studied symptoms, symptom distress and trade-off among long-term survivors and compared figures to those of population controls and patients who had undergone cystectomy.
MATERIALS AND METHODS: We identified 71 patients who had had urinary bladder cancer treated with radical radiotherapy before 1995. For comparison, 325 patients treated with radical cystectomy and urostomy, continent or non-continent, during the same period and 460 individuals randomly selected from the general population were included. Information was collected by means of an anonymously answered postal questionnaire to avoid investigator-related bias.
RESULTS: Answers were obtained from 58 (82%) radiated patients, 251 (85%) cystectomized patients and 310 (71%) population controls. Of the radiated patients, 74% reported little or no distress from symptoms from the urinary tract, 38% had had intercourse the previous month and 57% (men) reported they had ejaculated. Among the cystectomized patients, 13% had had intercourse and 0% (men) had ejaculated. Moderate or much distress from symptoms from the gastrointestinal tract was reported by 32% of the radiated patients, 24% of the cystectomized patients and 9% of the population controls. After radical radiotherapy, 46% of the patients were willing to accept some risk of decreased survival to become symptom-free.
CONCLUSIONS: About 3/4 of these long-term survivors after radical radiotherapy for bladder cancer had a functioning urinary bladder with little or no distress from the urinary tract. The prevalence of sexual dysfunction was lower than after cystectomy and the prevalence of distress from the gastrointestinal tract was comparable.

Entities:  

Mesh:

Year:  2002        PMID: 11937249     DOI: 10.1016/s0167-8140(01)00455-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

1.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 2.  [Noninvasive and invasive bladder cancer: diagnostics and treatment].

Authors:  P J Goebell; F Vom Dorp; C Rödel; D Frohneberg; J W Thüroff; D Jocham; C Stief; S Roth; R Knüchel; K W Schmidt; I Kausch; D Zaak; C Wiesner; K Miller; R Sauer; H Rübben
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

3.  In favour of bladder preservation using combined modality treatment.

Authors:  Himu Lukka
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

4.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

5.  Gastrointestinal complications of pelvic radiotherapy: are they of any importance?

Authors:  J Andreyev
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 6.  Trimodality therapy in bladder cancer: who, what, and when?

Authors:  Christopher Premo; Andrea B Apolo; Piyush K Agarwal; Deborah E Citrin
Journal:  Urol Clin North Am       Date:  2015-05       Impact factor: 2.241

Review 7.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

Review 8.  [Multimodal therapy for bladder sparing with high grade bladder tumors].

Authors:  P J Goebell; W Legal; C Weiss; R Fietkau; B Wullich; S Krause
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

9.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Donald S Kaufman; Michael P Hagan; Niall M Heney; Howard M Sandler
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 10.  Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy.

Authors:  Michael A Feuerstein; Anuj Goenka
Journal:  Curr Urol Rep       Date:  2015-11       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.